Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients

NCT00204607 ↗

Phase 1/2 Completed 20 enrolled University Hospital Tuebingen

Non-randomizedSingle-groupOpen-labelTreatment

Summary

vaccination protocol to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen

Timeline

Start: 2004-07
Primary completion: —
Completion: 2007-01

Publications

Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother. 2009 Jun;32(5):498-507. doi: 10.1097/CJI.0b013e3181a00068.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	mRNA	Messenger RNA (mRNA)	—	Intrathecal
Background	sargramostim	Protein / enzyme biologic	—	Subcutaneous

Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients

Summary

Timeline

Publications

Drugs

Indications